Triple reuptake inhibitors: The next generation of antidepressants

Current Neuropharmacology

Volumn 6, Issue 4, 2008, Pages 338-343

  Marks, David M ^a   Pae, Chi Un ^a,b   Patkar, Ashwin A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE HYDROCHLORIDE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BICIFADINE; BROMOCRIPTINE; CITALOPRAM; DOV 102677; DOV 216303; DOV 21947; DULOXETINE; ESCITALOPRAM; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N METHYL 3 HYDROXY 2 (2' NAPHTHYL) 3 PHENYLPROPYLAMINE; N,N DIMETHYL 3 CYCLOHEXYL 3 HYDROXY 2 (2' NAPHTHYL)PROPYLAMINE; NEFAZODONE; NORADRENALIN; NS 2330; PERGOLIDE; PLACEBO; PRC 025; PRC 050; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TESOFENSINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPLE REUPTAKE INHIBITOR; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; CHRONIC PAIN; CLINICAL RESEARCH; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROTRANSMISSION; NONHUMAN; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC TRANSMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 66149110404     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015908787386078     Document Type: Review

References (56)

1. Author. Title. Available at www.neurosearch.com. access date on 2/15/ 2008.
2. Axelrod, J., Whitby, L.G., Hertting, G. (1961) Effects of psychotropic drugs on the uptake of 3H-norepinephrine by tissues. Science, 133, 383-4.
3. Basile, A.S., Janowsky, A., Golembiowska, K., Kowalska, M., Tam, E., Benveniste, M., Popik, P., Nikiforuk, A., Krawczyk, M., Nowak, G., Krieter, P.A., Lippa, A.S., Skolnick, P., Koustova, E. (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J. Pharmacol. Exp. Ther., 321(3), 1208-25.
4. Beer, B., Stark, J., Krieter, P., Czobar, P., Beer, G., Lippa, A., Skolnick, P. (2004) DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J. Clin. Pharmacol., 44, 1360-7.
5. Bodkin, J.A., Lasser, R.A., Wines, J.D., Gardner, D.M., Baldessarini, R.J. (1997) Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry, 58, 137-45.
6. Czeh, B., Michaelis, T., Watanabe, T., From, J., De Biurrun, G., Van Kampen, M. (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. USA, 98(22), 12796-801.
7. D'Aquilla, P.S., Collu, M., Gessa, G.L., Serra, G. (2000) The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol., 405, 365-73.
8. Delgado, P.L. How antidepressants help depression: mechanisms of action and clinical response. (2004) J. Clin. Psychiatry, 65 (Suppl 4), 25-30.
9. Delgado, P.L., Millar, H.L., Saloman, R.M., Licinio, J., Heninger, G.R., Gelenberg, A.J., Charney, D.S. (1993) Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychpharmacol. Bull., 29, 389-96.
10. Drimmer, E.L., Gitlin, N.H., Gwirtsman, H.E. (1983) Desipramine and methylphenidate combination treatment for depression: case report. Am. J. Psychiatry, 14, 241-3.
11. Entsuah, A.R., Huang, H., Thase, M.E. (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry, 62, 869-77.
12. Fava, M. (2001)Augmentation and combination strategies in treatment resistant depression. J. Clin. Psychiatry, 62, 4-11.
13. Fawcett, J., Kravitz, H.M., Zejecka, J.M., Schaff, M.R. (1991) CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J. Clin. Psychopharmacol., 11, 127-32.
14. Feigner, J.P., Herbstein, J., Damlovji, N. (1985) Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J. Clin. Psychiatry, 46, 206-9.
15. Frackiewicz, E.J., Jhee, S.S., Shiovitz, T.M., Webster, J., Topham, C., Dockens, R.C., Whigan, D., Salazar, D.E., Cutler, N.R. (2002) Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann. Pharmacother., 36, 225-230.
16. Frantz, S. (2005) Drug discovery: playing dirty. Nature, 437, 942-3.
17. Guelfi, J.D., White, C., Hackett, D., Guichoux, J.Y., Magni, G. (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry, 56, 450-458.
18. Gwirtsman, H.E., Szuba, M.P., Toren, L., Feist, M. (1994) The antidepressant response to tricyclics in major depressives is accelerated with adjuctive use of methylphenidate. Psychopharmacol. Bull., 30(2), 157-64.
19. Hauser, R.A., Salin, L., Juhel, N., Konyago, V.L. (2007) Randomized trial of the triple monoamine reuptake inhibitor NS2330 (Tesofensine) in early Parkinson's disease. Mov. Disord., 22(3), 359-65.
20. Inoue, T., Tscuchiya, K., Miura, J., Sakakibara, S., Denda, K., Kasahara, T., Koyama, T. (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol. Psychiatry, 40, 151-3.
21. Izumi, T., Inoue, T., Kitagawa, N., Nishi, N., Shimanaka, S., Takahashi, Y., Kusumi, I., Odagaki, Y., Denda, K., Ohmori, T., Koyama, T. (2000) Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J. Affect Disord., 61,127-132.
22. Kasper, S., Spadone, C., Verpillat, P., Angst, J. (2006) Onset of action of escitalopram compared to other antidepressants: results of a pooled analysis. Int. Clin. Psychopharmacol., 21(2), 105-10.
23. Kazuto, Y., Tsujita, R., Ogawa, K., Hokonohara, T., Yamashita, K., Morino, K., Matsuda, A., Shuto, S. (2002) Bioorg. Med. Chem., 10, 1777.
24. Kennedy, S.H., Andersen, H.F., Lam, R.W. (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analyis. J. Psychiatry Neurosci., 31(2), 122-31.
25. Kiortsis, D.N., Tsouli, S., Fillipatos, T.D., Konitsiotis, S., Elisaf, M.S. (2008) Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr. Metab. Cardiovasc. Dis., 18(3), 207-10.
26. Larsen, M.H., Rosenbrock, H., Sams-Dodd, F., Mikkelsen, J.D. (2007) Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine reuptake inhibitor tesofensine. Eur. J. Pharmacol., 555, 115-121.
27. Masand, P.S., Anand, V.S., Tanquary, J.F. (1998) Psychostimulant augmentationof second generation antidepressants: a case series. Depress Anxiety, 7, 89-91.
28. McMillen, B.A., Shank, J.E., Jordan, K.B., Williams, H.L., Basile, A.S. (2007) Effect of DOV 102,677 on the volitional consumption of ethanol by Myers'high ethanol-preferring rat. Alcohol Clin. Exp. Res., 31(11), 1866-71.
29. Naranjo, C., Tremblay, L.K., Busto, U.E. (2001) The role of the brain reward system in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 25, 781-823.
30. Nemroff, C.B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D.M., Thase, M.E. (2008) Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry, 63(4), 424-34.
31. Owens, M.J. (2004) Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J. Clin. Psychiatry, 65(Suppl 4), 5-10.
32. Papkostas, G.I., Thase, M.E., Fava, M., Nelson, J.C., Shelton, R.C. (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry, 62(11), 1217-27.
33. Paul, I.A. (2001) Excitatory amino acid signaling, major depression, and the action of antidepressants. Pharm. News, 8, 33-44.
34. Popik, P., Krawczyk, M., Golembiowska, K., Nowak, G., Janowsky, A., Skolnick, P., Lippa, A., Basile, A.S. (2006) Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol. Neurobiol., 26, 857-73.
35. Randrup, A., Munkvad, J., Fog, R., Gerlach, J., Molander, L., Kjellberg, B., Scheel-Kruger, J. (1975) Mania, depression and brain dopamine. In Essman, W.B., Valzelli, L. (Eds), Current Developments in Psychopharmacology, Spectrum Publications, New York: vol 2, 206-48.
36. Richelson, E. Pharmacology of antidepressants. (2001) Mayo Clin. Proc., 76, 511-27.
37. Roggen, H., Kehler, J., Stensbol, T.B., Hansen, T. (2007) Synthesis of enantiomerically pure milnacepran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorg. Med. Chem. Lett., 17, 2834-7.
38. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a Star*D report. Am. J. Psychiatry, 163, 1905-17.
39. Shaw, A.M., Boules, M., Zhang, Y., Williams, K., Robinson, J., Carlier, P.R., Richelson, E. (2007) Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur. J. Pharmacol., 555, 30-6.
40. Shelton, C.I. (2004) Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful. J. Clin. Psychiatry, 65(Suppl 17), 29-33.
41. Shelton, R.C. (2004) The dual-action hypothesis: does pharmacology matter? J. Clin. Psychiatry, 65(Suppl 17), 5-10.
42. Shuto, S., Ono, S., Imoto, H., Yoshii, K., Matsuda, A. (1998) J. Med. Chem., 41, 3507.
43. Skolnick, P. (2005) Dopamine and depression. In Schmidt W (ed), Dopamine and Glutamate in Psychiatric Disorders. Totowa: Humana Press, vol. 9, pp. 199-214.
44. Skolnick, P., Krieter, P., Tizzano, J., Basile, A., Popik, P., Czobor, P., Lippa, A. (2006) Preclinical and Clinical Pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev., 12(2), 123-34.
45. Skolnick, P., Popik, P., Janowsky, A., Beer, B., Lippa, A.S. (2003) Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur. J. Pharmacol., 461, 99-104.
46. Skolnick, P., Popik, P., Janowsky, A., Beer, B., Lippa, A.S. (2003) "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci., 73, 3175-79.
47. Stassen, H.H., Angst, J., Hell, D., Scharfetter, C., Szegedi, A. (2007) Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J. Clin. Psychiatry, 68(8), 1195-205.
48. Steffens, D.C., Krishnan, K.R.R., Helms, M.J. Are SSRIs better than TCAs? (1997) Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety, 6, 10-8.
49. Stoll, A.L., Pillay, S.S., Diamond, L., Workum, S.B., Cole, J.O. (1996) Mehyphenidate augmentation of selective serotonin reuptake inhibitors: a case series. J. Clin. Psychiatry, 57, 72-76.
50. Thase, M.E., Entsuah, A.R., Rudolph, R.L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry, 178, 234-41.
51. Thatte, U. (2001) NS2330 (Neurosearch). Curr. Opin. Investig. Drugs, 2, 1592-4.
52. Wharton, R.N., Perel, J.M., Dayton, P.G., Malitz, S. (1971) A potential clinical use for methylphenidate with tricyclic antidepressants. Am. J. Psychiatry, 127, 1619-25.
53. Wilkes, S. (2006) Buproprion. Drugs Today (Barc.), 42(10), 671-81.
54. Willner, P. Dopaminergic mechanisms in depression and mania. In Watson, S. (Ed.), Psychopharmacology: The Fourth Generation of Progress. Lippincott Williams & Wilkins, New York. On-line edition.
55. Young, S.N., Smith, S.E., Pihl, R.O., Ervin, F.R. (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology, 87, 173-7.
56. Zisook, S., Rush, J.A., Haight, B.R., Clines, D.C., Rockett, C.B. (2005) Use of brupropion in combination with serotonin reuptake inhibitors. Biol. Psychiatry, 59, 203-10.